2020 – 2021
Doctor of Pharmacy Fellowship Program

Accelerate your career with one of our 1-year fellowship programs.
WE HAVE BUILT A STRONG CORPORATE CULTURE AROUND OUR MISSION AND VALUES. SEATTLE GENETICS EMBODIES AN ENTREPRENEURIAL SPIRIT THAT ADVANCES BREAKTHROUGH THERAPIES, WHICH IS WHY WE ARE THE LEADER IN ANTIBODY-DRUG CONJUGATE TECHNOLOGY.

OUR MISSION

Seattle Genetics develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives.

OUR VALUES

**Passion for helping patients**
Revolutionizing therapy for people living with cancer

**Integrity**
Honesty, respect and trust guide us

**Scientific excellence**
Premier science empowers our passion

**Teamwork and mutual respect**
Shared dedication drives successful collaborations

**Innovation**
Entrepreneurial spirit advances breakthrough therapies

**Great work environment**
Commitment and opportunity inspire purposeful contribution
Transformative Therapies Targeting Cancer

Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives.

ADCETRIS® (brentuximab vedotin) uses the company’s industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors. Positive data from the enfortumab vedotin pivotal trial were presented at the American Society of Clinical Oncology in June 2019 and serve as the basis for a Biologics License Application to the FDA under its accelerated approval pathway. Both enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer use our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. We are leveraging our expertise in empowered antibodies and targeted therapies to build a portfolio of programs for hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Zug, Switzerland.

Our ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer.

**Antibody-Drug Conjugates (ADCs)**
ADCs harness the specificity of monoclonal antibodies and the potency of cytotoxic agents

**Targeting the outside of the cell:**
- Monoclonal antibodies (mAbs)

**Targeting signaling pathways inside the cell:**
- Kinase inhibitors

**Activating immune cells:**
- Tumor vaccines
- CAR-T; ACTR
- Checkpoint inhibitors

Various combinations of these novel modalities are likely to be the future of treatment in oncology.

YEARS: In oncology for 20+ years
SIZE: Largest biotechnology company in the Pacific Northwest
EMPLOYEES: 1,500+ employees worldwide
PASSION: Helping people with cancer
LEADERS: In antibody-drug conjugate (ADC) technology
COMMERCIAL PRODUCT: ADCETRIS® (brentuximab vedotin) for multiple CD30-expressing lymphomas
RESEARCH & DEVELOPMENT: >750 scientists dedicated to developing our next innovations, and medical and clinical researchers focused on improving patient outcomes with targeted treatment options, including three unique programs in ongoing pivotal clinical trials
COLLABORATIONS: Multiple ADC technology licensing agreements; co-development collaborations with other oncology industry leaders
LOCATIONS: Greater Seattle and South San Francisco, United States; Zug, Switzerland

These are investigational uses/agents and efficacy/safety have not been established. There is no guarantee that these agents will receive regulatory approval and become commercially available for uses being investigated.
Advancing Late-Stage Clinical Trials and an Expanding Development Portfolio

BRENTUXIMAB VEDOTIN

ADCETRIS® (brentuximab vedotin) is currently approved in the U.S. for six indications for certain CD30-expressing lymphomas. We continue to evaluate ADCETRIS in a broad clinical development program.

Hodgkin Lymphoma (HL)

- CheckMate 812: Relapsed HL (+ nivolumab)
- Frontline HL in patients 60+ (+ nivolumab)
- Second-line HL (+ nivolumab)
- CheckMate 744: Relapsed cHL (+ nivolumab) (pediatric)

LATE-STAGE PROGRAMS

We believe our multiple promising late-stage programs have the potential to help us achieve our goal of bringing additional new treatment options to patients in need.

- Enfortumab vedotin<sup>1</sup>: EV-301 – Urothelial cancer post-PD(L)-1 inhibitor
- Enfortumab vedotin<sup>1</sup>: EV-201 – Urothelial cancer post-PD(L)-1 inhibitor
- Enfortumab vedotin<sup>1</sup>: EV-103 – First-line urothelial cancer (+ pembrolizumab and/or chemotherapy)
- Tisotumab vedotin<sup>2</sup>: innovaTV 204 – Cervical cancer (monotherapy)
- Tisotumab vedotin<sup>2</sup>: innovaTV 205 – First-line cervical cancer
- Tisotumab vedotin<sup>2</sup>: innovaTV 207 – Other solid tumors
- Tisotumab vedotin<sup>2</sup>: innovaTV 208 – Ovarian cancer
- Tucatinib: HER2CLIMB – HER2-positive breast cancer
- Tucatinib: I-SPY 2 – neoadjuvant breast cancer

EARLY-STAGE PROGRAMS

- Ladiratuzumab vedotin<sup>1</sup>: I-SPY 2 – HER2-negative breast cancer
- Ladiratuzumab vedotin: KEYNOTE 721 – Triple negative breast cancer (TNBC) (+ pembrolizumab)
- Ladiratuzumab vedotin: MORPHEUS – TNBC (+ atezolizumab)
- Ladiratuzumab vedotin: Breast cancer
- SEA-BCMA: Multiple myeloma
- ACTR-BCMA<sup>3</sup>: Multiple myeloma

<sup>1</sup> Program being developed in collaboration with Astellas
<sup>2</sup> Program being developed in collaboration with Genmab
<sup>3</sup> Program being developed in collaboration with Unum

These are investigational uses/agents and efficacy/safety have not been established. There is no guarantee that these agents will receive regulatory approval and become commercially available for uses being investigated.

For more information on our company and our robust pipeline, we encourage you to visit www.seattlegenetics.com.
Oncology Marketing

The Oncology Marketing Fellowship at Seattle Genetics offers a unique opportunity to pair one’s PharmD training with hands-on commercial experience in biotechnology. The fellow will assist and lead a variety of projects within the Marketing group while interacting with personnel from Sales, Market Planning and Managed Markets as well as key cross-functional groups, including Medical Affairs, Regulatory Affairs, Clinical Development, and Health Economics and Outcomes Research. The fellow will also have opportunities to participate in strategic marketing initiatives, including the development of brand and tactical plans.

SPECIFIC RESPONSIBILITIES WILL INCLUDE:

- Leverage clinical insights to develop impactful marketing tools in collaboration with internal stakeholders and agency partners
- Manage the development and execution of select branded and unbranded promotional materials
- Coordinate key logistical activities, notably those related to the promotional review committee, promotional material fulfillment, and national congress planning
- Summarize key insights from emerging clinical data in the oncology space to inform projects and initiatives within the commercial organization
- Manage advertising agencies and other commercial vendors
- Develop and deliver presentations as needed to the marketing team and other internal groups
- Participate in commercial strategy planning and brand plan development
- Travel may include, but is not limited to, attendance at key sales and marketing meetings, as well as attendance at annual ASCO, ASH and ASHP meetings

“As Seattle Genetics transitions into a multi-product, global oncology company, this fellowship position within the commercial organization enables our fellow to be an important member of the marketing team as we continue to support our approved indications for ADCETRIS in North America, as well as support our late-stage assets. This opportunity provides a well-rounded experience that will set a solid foundation for a successful career within the biopharmaceutical industry.”

Matt Skelton
Vice President, Marketing
The Drug Safety Fellowship at Seattle Genetics offers an opportunity to apply one’s clinical knowledge and analytical skills while gaining a thorough understanding of pharmacovigilance across the product life cycle. Fellows will work closely with the Safety Surveillance and Epidemiology Lead and the Risk Management Lead in single case evaluation, aggregate data analysis, signal detection and assessments. Additionally, the fellows will have the opportunity to gain experience through strategic interactions with key cross-functional team members, such as Non-Clinical Development, Drug Safety Operations, Drug Safety Epidemiology, Clinical Development, Clinical Information Systems, Regulatory Affairs and Medical Affairs.

SPECIFIC RESPONSIBILITIES WILL INCLUDE:

- Contribute to Pharmacovigilance and Risk Management (RM) planning for designated products
- Track and evaluate potential safety issues
- Support the development of periodic aggregate safety reports
- Perform Project Management activities for multiple studies in a program
- Generate and complete a longitudinal project(s), with publication and/or presentation opportunities
- Develop and deliver presentations as needed to Drug Safety and other internal groups
- Support the RM lead in the development and/or execution of Risk Management Plans or Risk Evaluation and Mitigation Strategies
- Conduct/support signal detection and evaluation according to standard operating procedures and guidelines
- Prepare Safety Reports as necessary for safety signals or other issues (product quality)
- Provide safety content review of clinical protocols, study reports, informed consent forms and Investigator Brochures for designated products
- Support the RM Lead in responding to safety requests for assigned product(s) from Regulatory Authorities, Affiliates and other internal functions
- Attend weekly SS&E meeting to relay safety concerns raised in Study Team/Clinical Sub Team Meetings
- Travel may include, but is not limited to, the annual ASHP meeting

“The Drug Safety fellowship is a fantastic opportunity for a fellow to jumpstart his/her career in pharmacovigilance during an exciting time at Seattle Genetics.”

Sundos Hamza, MD
Senior Vice President, Risk Management and Pharmacovigilance
Oncology Medical Affairs

The Medical Affairs Fellowship represents an excellent opportunity for PharmDs to gain biopharmaceutical industry experience and expand their clinical knowledge through active participation on the Medical Affairs team. The fellow will have the opportunity to obtain an understanding of the role of Medical Affairs in the biopharmaceutical industry; develop clinical data analysis, interpretation and communication skills; recognize unmet patient needs and render clinical insights; and develop industry-appropriate professional skills. The fellow will actively participate and contribute to the Medical Information, Medical Communications, Clinical Value and Outcomes, Scientific Alliances, Medical Education, Medical Director, and Medical Science Liaison teams, while collaborating with key cross-functional groups, including Commercial, Regulatory, and Clinical Development.

SPECIFIC RESPONSIBILITIES WILL INCLUDE:

- Developing skills across a broad set of Medical Affairs-related areas
- Contributing to scientific communication platforms and engaging in scientific exchange
- Supporting Medical Affairs at large national scientific meetings by developing scientific communication materials and graphics, with scientific engagement opportunities
- Creating and executing longitudinal projects, with publication and/or presentation opportunities
- Developing and delivering presentations as needed to Medical Affairs and other internal groups
- Using clinical expertise and insights to inform Medical Affairs projects and initiatives
- Cross-functional collaboration across Seattle Genetics, as well as interfacing with external stakeholders that may include healthcare professionals, payers, corporate partners and others

“The Medical Affairs Fellowship provides an excellent opportunity to build skills in clinical data analysis, scientific communication, and engagement with internal and external cancer experts to help translate science into improving patient outcomes.”

Michelle Ubowski, PharmD
St. John Fisher College

Gerald Engley, PharmD
Executive Director, Medical Affairs
Pharmacy Fellowship Director
The Seattle Genetics Regulatory Affairs Fellowship provides a unique opportunity for a PharmD graduate to gain training and hands-on experience in a specialized area of Regulatory Science. The fellow will work closely with the Regulatory Affairs – Advertising and Promotion Lead on marketed and development-stage products. The fellow will have the opportunity to interact cross-functionally with a broad group of team members and key stakeholders, including: Clinical Value and Outcomes, Corporate Communications, Health Economics and Outcomes Research, Investor Relations, Legal Affairs, Marketing, Medical Affairs, and Regulatory Affairs.

**SPECIFIC RESPONSIBILITIES WILL INCLUDE:**

- Monitoring, analyzing, and summarizing FDA Office of Prescription Drug Promotion (OPDP) enforcement actions and evolving regulatory guidance
- Coordinating OPDP regulatory submissions
- Participating in the review of, and provide regulatory advice on, promotional materials, non-promotional medical/scientific communications, and national congress assets
- Developing and delivering presentations as needed to the promotional review committee and other internal groups
- Working collaboratively with internal partners and stakeholders
- Travel opportunities such as ASCO, ASH, and ASHP meetings
- Opportunity to help shape the fellowship for future applicants

“\n\nThe Regulatory Affairs — Advertising and Promotion Fellowship is a unique opportunity to work with colleagues in diverse roles and contribute to Seattle Genetics’ vision to address the unmet needs of patients through innovative science. This Fellowship is an opportunity to develop the knowledge and skills to support a career in Regulatory Affairs through direct hands-on experience supporting ADCETRIS and our expanding pipeline.”

Leanne Griffin, RAC
Director, Regulatory Ad/Promo
The Seattle Genetics Regulatory Affairs Fellowship provides a unique opportunity for a PharmD graduate to gain training and hands-on experience in a specialized area of Regulatory Science. The fellow will work closely with the Regulatory Affairs – Labeling Lead on marketed and late-stage development products. The fellow will have the opportunity to work cross-functionally with key stakeholders to develop labeling documents, support strategic labeling development, label negotiations with Health Authorities, label expansions, and support global marketing authorization applications. The fellow will interact cross-functionally with a broad group of team members and key stakeholders, including: Clinical Research, Drug Safety, Marketing, Translational Science, Medical Affairs, Legal Affairs, and Regulatory Affairs.

**SPECIFIC RESPONSIBILITIES WILL INCLUDE:**

- Supporting the development and maintenance of Target Product Labels, Company Core Data Sheets, USPIs and Product Monographs
- Participating in the authoring and cross-functional review of labeling documents with subject matter experts
- Supporting the preparation of labeling documents for new marketing authorization applications and supplemental applications
- Supporting Health Authority label negotiations
- Analyzing, researching, and presenting on competitor labels and labeling precedents
- Developing and delivering presentations as needed to the promotional review committee and other internal groups
- Working collaboratively with internal partners and stakeholders
- Opportunity to help shape the fellowship for future applicants

“"The Regulatory Affairs Labeling Fellowship is an exciting opportunity to support Seattle Genetics' growing late-stage portfolio. This fellowship offers exposure to key regulatory milestones including global marketing authorization applications and label expansions to bring innovative therapies to patients.”

Jenny Wang, MS
Director, Regulatory Labeling
Oncology Medical Writing

The Oncology Medical Writing fellow will gain experience through rotations focusing on regulatory medical writing, publication authoring and development, and clinical trial transparency and disclosure. The fellow will also interact with key cross-functional groups within Seattle Genetics, particularly across the Development organization, including: Regulatory, Clinical Operations, Biostatistics, Clinical Programming, Clinical Research, Medical Affairs, and Drug Safety, providing support for Seattle Genetics’ marketed products and pipeline programs.

SPECIFIC RESPONSIBILITIES WILL INCLUDE:

• Active participation in Medical Writing-related teams/working groups
• Analyze and interpret statistical output and study results for inclusion in clinical and regulatory documents
• Participate in cross functional discussion to align on interpretation and presentation of results
• Authoring and developing content for varied audiences:
  - Regulatory (Protocols, IBs, CSRs, Clinical Summaries)
  - Publications (Abstracts, Presentations, Posters)
  - Patient Facing (ICFs, lay summaries)
  - Clinical Trial Disclosure (Registration, summaries and results postings)
• Develop understanding of the regulations and guidances that affect the medical processes and deliverables
• Represent Medical Writing on cross functional project and program teams
• Participation in professional skills courses
• Travel may include attendance at Medical Writing-focused or industry-specific conferences

“The medical writing fellowship provides an opportunity to gain hands on experience in authoring and developing a broad range of clinical and regulatory documents through diverse cross-functional collaborations in a dynamic setting to foster continued growth at Seattle Genetics.”

Robert Graser
Senior Director, Medical Writing
Clinical Development Operations

The Seattle Genetics Clinical Development Operations, Clinical Scientist Fellowship provides a unique opportunity for a PharmD graduates to gain hands-on experiences in the conduct of Oncology Clinical Trials from both operational and clinical perspectives, with a focus on professional development towards a clinical scientist role. Throughout this period, fellows will be exposed to a rich team environment where they will be able to collaborate with and learn from cross-functional team members, including Clinical Project Management, Clinical Trial Management, Data Management, Medical Monitors, Regulatory Affairs, Clinical Supplies, Biostatistics / Programming and Medical Writing.

SPECIFIC RESPONSIBILITIES WILL INCLUDE:

- Involvement in clinical study conduct ranging from initiation to closure activities and may include the following:
  - Protocol, abstract, manuscript, and clinical study report development
  - Vendor setup and management
  - Risk and quality plan development
  - Clinical data review
  - Database lock
- Opportunity to travel to local investigational sites with Field Clinical Research Associates and engage in clinical site management and monitoring
- Prepare presentations for and participate in Investigators’ Meetings, Advisory Boards and Steering Committee meetings
- Serve as a scientific and medical resource for design and interpretation of clinical and preclinical programs to support existing and new development candidates
- Evaluation of safety, pharmacology, and efficacy data from ongoing and completed studies
- Potential opportunities to attend key industry meetings such as DIA, ASCO, ASH, and ASHP meetings
- Cross-functional collaboration within Seattle Genetics, as well as interface with external stakeholders that may include healthcare professionals, corporate partners and others

“This is an exciting time at Seattle Genetics where the company is making tremendous strides to grow the clinical development pipeline to bring value to many patients with unmet medical needs. The clinical development operations fellowship is a tremendous opportunity to be part of an ecosystem with many talented and experienced colleagues eager to share their perspectives.”

Kamran Ansari
Vice President, Clinical Development Operations
Working at Seattle Genetics

Seattle Genetics, Inc. is a premier biotech company that is passionate about improving the lives of patients. Join us in accomplishing our mission… and enjoy other aspects of the company such as a collaborative culture, great benefits and top-notch talent!

HERE’S A BRIEF SNAPSHOT OF OUR COMPANY CULTURE

- Multiple locations in the Greater Seattle area, and South San Francisco; close to major highways, dining and shopping
- Weekly all-company meetings led by the CEO
- Training opportunities for employee growth including leadership and skill-building
- After-work activities, including softball teams, dodgeball and basketball tournaments
- Company-sponsored philanthropic opportunities including Light The Night, Obliteride, Toys for Tots and a food drive for Hopelink
- Monthly happy hours
- On-site yoga classes and sport court
- Education assistance program
- Frequent celebrations including annual holiday party

BENEFITS HIGHLIGHTS

At Seattle Genetics we believe that team members are the key to success. Here is a sample of the competitive benefits offered by Seattle Genetics.

- A competitive compensation and benefits package (including stock options, restricted stock, medical, dental, vision, life and disability insurance, employee stock purchase plan and 401(k) plan)
- Paid vacation — Three to five weeks paid vacation, based on length of service
- Sick time — Employees accrue two weeks per year
- Holiday schedule — Fixed holidays and a winter break between Christmas and New Year’s Day
- Sabbatical — Full-time employees are eligible for a sabbatical with full pay and benefits based on years of service. This is an opportunity for personal or professional development, or simply a time to recharge
- Multiple leave options to help support work-life balance
- Employee discounts to Woodland Park Zoo, 24 Hour Fitness, AT&T and Verizon Wireless
Application Requirements 2020-2021

ELIGIBILITY

• All candidates must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy prior to fellowship start date.

• All candidates must have authorization to work in the United States throughout the duration of the one-year fellowship. No visa sponsorship will be provided.

Seattle Genetics is an equal opportunity employer. All qualified applications will receive consideration for employment without regard to race, age, gender identity, sexual orientation, color, religion, sex, marital status, national origin, protected veteran status, disability status, or any other status protected by federal, state, or local law.

How to Apply

Candidates may request an interview through the American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting Personnel Placement Service (PPS). In addition, applicants must upload the following application materials with the interview request through PPS by November 27th, 2019:

• Curriculum vitae

• Letter of intent

• 3 letters of recommendation are required for onsite interview at Seattle Genetics

General Program Inquiries: fellowship@seagen.com

FELLOWSHIPS WILL
START IN JUNE OF 2020
AND RUN FOR ONE YEAR